GeneMind Biosciences (真迈生物) is a Shenzhen-based life-sciences company that develops gene sequencing platforms. Its SURFSeq series sequencers carry China NMPA Class III medical device registration and serve customers in more than 50 countries. In September 2026 it closed a roughly CNY 587.5M Series D jointly led by a consortium of state-backed investors including Shanghai International Group Investment, Shenzhen Capital Group, Shengwei Rongquan Fund and Guoxin Fund to fund innovation, product delivery and global expansion.
1
Round
1
Industry
4
Tags
Sep 14, 2026
Latest raise
Funding activity · 1 round
Sep 14, 2026
CNY 587.5M
Series C+
Led by Shenzhen Capital Group
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
